Skip to main navigation Skip to search Skip to main content

Clinical evaluation of the bispecific antibody MDX-H210 (anti FcRI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (Filgramostim) for treatment of advanced breast cancer

  • H.H. van Ojik
  • , R. Repp
  • , G. Groenewegen
  • , T. Valerius
  • , J.G.J. van de Winkel
  • University Medical Center Utrecht
  • extern

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)207-209
Number of pages3
JournalCancer Immunology, Immunotherapy
Volume45
Publication statusPublished - 1997

Bibliographical note

keypublication

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this